979 related articles for article (PubMed ID: 26540567)
1. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
2. Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.
Redondo-Muñoz J; Escobar-Díaz E; Hernández Del Cerro M; Pandiella A; Terol MJ; García-Marco JA; García-Pardo A
Clin Cancer Res; 2010 Sep; 16(17):4382-91. PubMed ID: 20534739
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; García-Marco JA; García-Pardo A
Oncotarget; 2016 Dec; 7(50):83359-83377. PubMed ID: 27829220
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.
Lozano-Santos C; Amigo-Jiménez I; Nova-Gurumeta S; Pérez-Sanz N; García-Pardo A; García-Marco JA
Biochem Biophys Res Commun; 2015 May; 461(2):243-8. PubMed ID: 25869069
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide.
Amigo-Jiménez I; Bailón E; Ugarte-Berzal E; Aguilera-Montilla N; García-Marco JA; García-Pardo A
PLoS One; 2014; 9(6):e99993. PubMed ID: 24956101
[TBL] [Abstract][Full Text] [Related]
6. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
Bojarczuk K; Sasi BK; Gobessi S; Innocenti I; Pozzato G; Laurenti L; Efremov DG
Blood; 2016 Jun; 127(25):3192-201. PubMed ID: 27095788
[TBL] [Abstract][Full Text] [Related]
7. STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia.
Liu FT; Jia L; Wang P; Wang H; Farren TW; Agrawal SG
Oncotarget; 2016 May; 7(22):32031-45. PubMed ID: 27074565
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib.
Bashash D; Safaroghli-Azar A; Dadashi M; Safa M; Momeny M; Ghaffari SH
Int J Biochem Cell Biol; 2017 Apr; 85():149-158. PubMed ID: 28254430
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia.
Balakrishnan K; Burger JA; Fu M; Doifode T; Wierda WG; Gandhi V
Neoplasia; 2014 Dec; 16(12):1036-46. PubMed ID: 25499217
[TBL] [Abstract][Full Text] [Related]
10. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
Lu K; Fang XS; Feng LL; Jiang YJ; Zhou XX; Liu X; Li PP; Chen N; Ding M; Wang N; Zhang J; Wang X
Cancer Lett; 2015 Apr; 359(2):250-8. PubMed ID: 25636517
[TBL] [Abstract][Full Text] [Related]
11. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.
Modi P; Balakrishnan K; Yang Q; Wierda WG; Keating MJ; Gandhi V
Oncotarget; 2017 Mar; 8(10):16259-16274. PubMed ID: 28187444
[TBL] [Abstract][Full Text] [Related]
12. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
Choudhary GS; Al-Harbi S; Mazumder S; Hill BT; Smith MR; Bodo J; Hsi ED; Almasan A
Cell Death Dis; 2015 Jan; 6(1):e1593. PubMed ID: 25590803
[TBL] [Abstract][Full Text] [Related]
13. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.
Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
Leukemia; 2013 Feb; 27(2):315-24. PubMed ID: 22751450
[TBL] [Abstract][Full Text] [Related]
15. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia.
Goussetis DJ; Platanias LC
Clin Cancer Res; 2010 Sep; 16(17):4311-2. PubMed ID: 20622048
[TBL] [Abstract][Full Text] [Related]
17. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
[TBL] [Abstract][Full Text] [Related]
18. Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia.
van Attekum MHA; Terpstra S; Slinger E; von Lindern M; Moerland PD; Jongejan A; Kater AP; Eldering E
Oncogene; 2017 Jun; 36(26):3651-3660. PubMed ID: 28192408
[TBL] [Abstract][Full Text] [Related]
19. TG-interacting factor transcriptionally induced by AKT/FOXO3A is a negative regulator that antagonizes arsenic trioxide-induced cancer cell apoptosis.
Liu ZM; Tseng HY; Cheng YL; Yeh BW; Wu WJ; Huang HS
Toxicol Appl Pharmacol; 2015 May; 285(1):41-50. PubMed ID: 25791921
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
Li Y; Qu X; Qu J; Zhang Y; Liu J; Teng Y; Hu X; Hou K; Liu Y
Cancer Lett; 2009 Nov; 284(2):208-15. PubMed ID: 19457607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]